financetom
Business
financetom
/
Business
/
Hertz Stock Is Moving Higher After Hours: Here's Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hertz Stock Is Moving Higher After Hours: Here's Why
Sep 23, 2025 2:21 PM

Hertz Global Holdings Inc ( HTZ ) shares are moving higher in Tuesday’s after-hours session after the company announced it received notification of a settlement distribution.

Check out HTZ stock here.

What Happened: Hertz said it will receive a pro rata settlement distribution of approximately $154.05 million in connection with the company’s participation in a class action settlement, Automotive Parts Antitrust Litigation.

Hertz expects the settlement distribution to be paid on or around Sept. 30. The company had approximately $503 million in total cash and cash equivalents as of June 30.

How To Buy HTZ Stock

By now, you're likely curious about how to participate in the market for Hertz — be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option or sell a call option at a strike price above where shares are currently trading — either way, it allows you to profit from the share price decline.

HTZ Price Action: Hertz shares were up 2.01% in after-hours, trading at $7.10 at the time of publication on Tuesday, according to Benzinga Pro.

Read Next:

Micron Stock Seesaws On Q4 Earnings Beat, Strong Guidance As Company Focuses On AI Opportunity

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Granite Tapped for $48 Million Fish Highway Crossing in Washington
Granite Tapped for $48 Million Fish Highway Crossing in Washington
May 23, 2024
05:11 PM EDT, 05/23/2024 (MT Newswires) -- Granite (GVA) late Thursday said it has received a $48 million contract from the Washington State Department of Transportation to replace two fish barrier culvert crossings north of Seattle on Interstate Highway 5. Funding for the three new fish passageways on Secret Creek in Snohomish County will be provided by the state highway...
Morningstar Insider Sold Shares Worth $3,890,140, According to a Recent SEC Filing
Morningstar Insider Sold Shares Worth $3,890,140, According to a Recent SEC Filing
May 23, 2024
05:11 PM EDT, 05/23/2024 (MT Newswires) -- Joseph D Mansueto, 10% Owner, Director, Executive Chairman, on May 21, 2024, sold 13,009 shares in Morningstar ( MORN ) for $3,890,140. Following the Form 4 filing with the SEC, Mansueto has control over a total of 15,577,585 shares of the company, with 10,674,922 shares held directly and 4,902,663 controlled indirectly. SEC Filing:...
Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
May 23, 2024
05:13 PM EDT, 05/23/2024 (MT Newswires) -- Eupraxia Pharmaceuticals Inc. ( EPRX ) , a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, after trade Thursday announced that regulators in Australia and Canada have cleared the company's request to expand its Phase 1b/2a RESOLVE trial, which is evaluating the safety...
U.S. FDA advisers back approval for Guardant's blood-based cancer test
U.S. FDA advisers back approval for Guardant's blood-based cancer test
May 23, 2024
(Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's ( GH ) blood test to detect a cancer that begins in the colon or rectum. The panel voted seven-to-two in favor of benefits outweighing risks when using the test called Shield for colorectal cancer (CRC). If approved, Shield could become...
Copyright 2023-2026 - www.financetom.com All Rights Reserved